Signals, Powered By EquityPandit
DUSA Pharmaceuticals, a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd. has received relief from a U.S. court in a patent infringement case. According to Sun Pharma regulatory filing, Massachusetts-based DUSA has been granted preliminary injunctive relief by a federal district court prohibiting defendants Biofrontera Inc, Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, and Biofrontera AG from using its confidential and proprietary trade secret information.
The lawsuit which was filed by DUSA earlier this year in the U.S. District Court for the District of Massachusetts alleged that Biofrontera defendants, misappropriated trade secret and caused a patent infringement of DUSA’s photodynamic therapy patents covering its product.
In July, DUSA in its amended complaint alleged that the Biofrontera defendants misappropriated confidential and trade secret information by obtaining confidential information from its former employees to sell and market defendants’ own products.
Sun Pharma also added that the court’s order prohibits Biofrontera from making use of or disseminating DUSA’s sales and financial information, customer lists and customer target lists, training and marketing materials, standard operating procedures, technical information, and unpublished clinical data, and any derivations thereof, effective immediately.
